Of everything that goes untreated after menopause, this is the clearest example. Painful sex affects a large proportion of postmenopausal women. Surveys consistently find that most affected women never raise it, and that most clinicians never ask.
The result is a treatable condition with well-supported therapy sitting in silence on both sides of the desk. For a practice, that is both a clinical failure and an unserved need.
Article Summary:
| Painful sex after menopause is common, treatable, and routinely undiscussed by both patients and clinicians. |
| Most presentations are physical rather than psychological, and treating the pain resolves more than a conversation about desire will. |
| The clinical barrier is that nobody asks. Adding one screening question changes case identification more than any device. |
| This is a service with well-supported treatment, which distinguishes it from much of what is marketed in this space. |
What patients are actually presenting with
Most cases fall under genitourinary syndrome of menopause, which covers vaginal dryness, pain with sex, itching and burning, urinary urgency and frequency, and recurrent urinary tract infections.
As estrogen falls, vaginal tissue thins and loses elasticity, lubrication reduces, blood flow drops and vaginal pH rises. The symptoms follow directly from those tissue changes, which is why the presentation is physical rather than psychological.
It also explains the sequence clinicians should learn to recognize. Sex becomes painful, it stays painful, and desire falls in response. By the time the patient mentions anything, the presenting complaint is often low libido, and the conversation moves to desire when the problem was always pain.
Why this progresses rather than resolving
Vasomotor symptoms tend to ease over years. Genitourinary symptoms do not, because the underlying tissue change continues while estrogen remains low.
Clinically this changes the cost of watchful waiting. Deferring treatment for hot flashes is a defensible choice. Deferring treatment here generally means a more established problem later and more years of avoidable discomfort in between.
The single change that identifies most cases
Ask. That is the intervention with the largest effect on case-finding in this area, and it costs nothing.
A direct, unembarrassed screening question in the intake or the review appointment does most of the work: whether the patient is experiencing vaginal dryness, discomfort with sex, or urinary symptoms. Framing it as a routine part of midlife assessment rather than a sensitive aside gives the patient permission to answer.
Patients will not volunteer this. Many have already tried once with another clinician and been redirected. If your intake form does not include it, your service does not include it either.
What treatment involves
The distinction between lubricants and vaginal moisturizers is worth teaching to every member of the clinical team, because it is almost never explained to patients. A lubricant is used at the time of sex and reduces friction in the moment. A moisturizer is used regularly, several times a week, and improves the condition of the tissue. They do different jobs and can be combined.
Local vaginal estrogen has the strongest evidence base for genitourinary syndrome of menopause and remains substantially under-used. It is applied directly to the tissue as a cream, tablet or ring, acts locally, and involves minimal systemic absorption. It also has evidence for reducing recurrent urinary tract infections, which brings a second patient group into the same conversation.
Two clarifications your team will need. Local vaginal estrogen is not the same as systemic hormone therapy, and the two carry different risk discussions. And local vaginal estrogen carried a boxed warning for many years that many clinicians considered unsupported for local treatment; the FDA began removing these warnings in November 2025. Patients who were previously advised against it on the basis of that label may reasonably revisit the decision.
Patients with a personal history of breast cancer, particularly those on an aromatase inhibitor, are managed alongside their oncology team rather than independently.
What must not be missed
A sexual health service needs clear escalation rules, because several conditions present similarly and require different management.
Any bleeding after twelve period-free months requires prompt assessment and should not be attributed to thin tissue without investigation. Updated guidance from the American College of Obstetricians and Gynecologists, published in April 2026, advises transvaginal ultrasound and endometrial sampling as the initial assessment together rather than sequentially.
Persistent vulvar itching warrants examination, as does a white or thickened patch, a lump, an ulcer, or a sore that does not heal. Lichen sclerosus becomes more common after menopause, produces similar symptoms, and requires different treatment and ongoing monitoring.
A word on devices and marketing claims
This is an area with aggressive marketing and uneven evidence, particularly around energy-based devices promoted for vaginal rejuvenation. Practices that lead with a device and treat local estrogen as an afterthought have the evidence hierarchy backwards.
Offer the treatment with the strongest evidence first, describe what any adjunct does and does not do, and be careful about claims. Credibility in midlife care is built slowly and lost quickly.
Getting the team ready
Clinician education is the starting point, and it needs to extend past the prescribing decision to the conversation itself. Most clinicians have never been taught how to open this subject, which is why it stays closed.
EncorVita’s education covers the assessment, the treatment evidence, and the patient conversation frameworks that make the assessment usable in a real appointment. Details are at academy.encorvita.com.
It affects a large proportion of postmenopausal women and is widely under-reported by patients and under-asked about by clinicians.
Generally not. Unlike vasomotor symptoms, genitourinary symptoms progress because the underlying tissue change continues while estrogen remains low.
No. It is applied directly to vaginal tissue, acts locally, and involves minimal systemic absorption. The risk discussion differs from that for systemic hormone therapy.
Local vaginal estrogen carried a boxed warning for years that many clinicians considered unsupported for local treatment. The FDA began removing these warnings in November 2025.
Management is individualized and undertaken alongside the patient’s oncology team, particularly for patients on an aromatase inhibitor.
Evidence is uneven and they should not displace treatments with stronger support. Any claims made in marketing should be defensible and specific.
